FCGR2A and neoplasm: The lysis of tumor cells mediated by CD19-DE was reduced to background with an FcγRIII (CD16) blocking antibody whereas the blockade of the FcγRIIa (CD32a) or of the complement system by eculizumab had no significant effect on the tumor cell killing of CD19-DE (Figure 4B).